Human trials under way at the University of Miami and other hospitals in Europe, Asia and Latin America using immature adult stem cells are showing promise for people with type 2 diabetes.
In a UM clinical trial recently published in the online journal Cell Transplantation, 25 patients achieved better insulin production, lower blood-sugar levels and reduced need for insulin injections.
In the trial, still in its pilot stage, doctors extracted immature adult stem cells from the patients’ own bone marrow, purified and concentrated them, and injected them into arteries near the pancreas. They then put the patients into hyperbaric oxygen chambers like those used for divers with decompression sickness — also called the ”bends” — and subjected them to 10 hours of pure oxygen at 2.4 times the atmospheric pressure at ground level.
Researchers believe the high-pressure oxygen pulled extra stem cells from the patients’ bone marrow, adding to the stem cells injected near the pancreas. They say the immature stem cells developed into pancreatic cells, regenerating the pancreas’ ability to produce natural insulin.
”This could be very important,” said Dr. Camillo Ricordi, director of the Cell Transplant Center and the Diabetes Research Institute at UM. “It could be an improved treatment for diabetes, substantially ameliorating type 2 and preventing the complications of the disease.”
Nearly 8 percent of the U.S. population — 24 million people — has diabetes, which can cause problems for the eyes, kidneys, nerves and heart, according to the Centers for Disease Control and Prevention.
Ricordi cautioned that the optimistic findings come from small pilot studies involving only dozens of patients, and three to four more years of research are needed before practical treatments might start.
”We always have to avoid hype and be careful not to put too much hope in pilot trials,” Ricordi said. “But the first results are really promising.”
Two more successful trials over three or four years would be needed before the FDA might approve the treatment. The studies, coordinated by UM’s Diabetes Research Institute, will also take place at the Karolinska Institutet in Stockholm, Stem Cell Argentina in Buenos Aires and other institutions.
Source: Miami Herald
Other articles and science reports on Adult Stem Cells.
Check, E., Cardiologists take heart from stem-cell treatment success, Nature 428(6986):880, 29 April 2004: "Adult stem cells have long been viewed as less flexible than embryonic stem cells, which can divide to produce any cell type in the body. But recent studies of human cells suggest that adult stem cells can also turn into many cell types, including heart, brain and liver cells."
Terada, N. et al., Bone marrow cells adopt the phenotype of other cells by spontaneous cells fusion, Nature (416(6880):542–545, 4 April 2002.
Cohen, P., Stem cells could save sight, New Scientist 175:(2354):18, 3 August 2002.
Stem cells do their stuff for Parkinson’s patient, New Scientist 174(2338):5, 13 April 2002.
Randerson, J., Stem cells fix the damage, New Scientist 177(2377):14, 11 January 2003.
Pluchino, S. et al., Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis, Nature 422(6933):688–694, 17 April 2003.
Jochen Ringe et al., Stem cells for regenerative medicine: advances in the engineering of tissues and organs, Naturwissenschaften 89(8), August 2002.
About the Formulator of StemEnhance - Christian Drapeau
Mr. Drapeau, a foremost scientist in the study of Aphanizomenon flos-aquae, holds a Masters of Science degree in Neurology and Neurosurgery from the Montreal Neurological Institute, an affiliate of McGill University in Montreal, Quebec, Canada. He has been extensively involved in the study of nutrition, naturopathy, and various natural therapies.
Most significantly, Mr. Drapeau collaborated with many scientists affiliated with Harvard University, McGill University, the University of Illinois, Oregon State University, the University of New Mexico, and the University of Mississippi in the study of the effects of blue-green algae (Aphanizomenon flos-aquae) on human health. Mr. Drapeau continues his involvement in the clinical study of AFA.
Circulating stem cells can reach various organs and become cells of that organ, helping such organ regain and maintain optimal health. Recent studies have suggested that the number of circulating stem cells is a key factor; the higher the number of circulating stem cells the greater is the ability of the body at healing itself. What happens to stem cells if they do not reach a tissue? Stem cells released from the bone marrow that do not reach a tissue simply return to the bone marrow after some timeCheck, E., Cardiologists take heart from stem-cell treatment success, Nature 428(6986):880, 29 April 2004: "Adult stem cells have long been viewed as less flexible than embryonic stem cells, which can divide to produce any cell type in the body. But recent studies of human cells suggest that adult stem cells can also turn into many cell types, including heart, brain and liver cells."
Terada, N. et al., Bone marrow cells adopt the phenotype of other cells by spontaneous cells fusion, Nature (416(6880):542–545, 4 April 2002.
Cohen, P., Stem cells could save sight, New Scientist 175:(2354):18, 3 August 2002.
Stem cells do their stuff for Parkinson’s patient, New Scientist 174(2338):5, 13 April 2002.
Randerson, J., Stem cells fix the damage, New Scientist 177(2377):14, 11 January 2003.
Pluchino, S. et al., Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis, Nature 422(6933):688–694, 17 April 2003.
Jochen Ringe et al., Stem cells for regenerative medicine: advances in the engineering of tissues and organs, Naturwissenschaften 89(8), August 2002.
About the Formulator of StemEnhance - Christian Drapeau
Mr. Drapeau, a foremost scientist in the study of Aphanizomenon flos-aquae, holds a Masters of Science degree in Neurology and Neurosurgery from the Montreal Neurological Institute, an affiliate of McGill University in Montreal, Quebec, Canada. He has been extensively involved in the study of nutrition, naturopathy, and various natural therapies.
Most significantly, Mr. Drapeau collaborated with many scientists affiliated with Harvard University, McGill University, the University of Illinois, Oregon State University, the University of New Mexico, and the University of Mississippi in the study of the effects of blue-green algae (Aphanizomenon flos-aquae) on human health. Mr. Drapeau continues his involvement in the clinical study of AFA.
United States Patent Patent No.: 6,814,961 B1 Date of Patent: November 9, 2004 Subj: METHOD FOR ENHANCING STEM CELL PHYSIOLOGY Inventors: Gitte S. Jensen and Christian Drapeau
